Table 1.

Summary of plausible pharmacological intervention in COVID-19 patients with obesity.

S. No.	Target	Therapy	Effects	Ref.
1.	TMPRSS	Camostat Mesylate (FOY-305)	Blocks TMPRSS activity, reducing entry of SARS-CoV-2 inside host cells	[84]
2.	ACE-2	Umifenovir (Arbidol)	Blocks the fusion of viral envelope with host cell membrane	[82] [83]
3.	RdRPs	Ribavirin, Remdesivir, and Favipiravir	Blocks the function of RdRPs and thus checks the incorporation of nucleotides in newly synthesized viral RNA	[85]
4.	Main protease (Mpro)	Withanone and Caffeic Acid-Phenethyl Ester	Demonstrated to prevent the proteolytic processing of the crucial polyproteins involved with viral replication & transcription	[88]
5.	IL-6	Tocilizumab and Sarilumab	IL-6 receptor agonist may prevent the IL-6 mediated signaling cascade & proinflammatory response	[90]
6.	IL-1β	Anakinra	IL-1β agonist may prevent the proinflammatory activity of heightened IL-1β in the organs and tissues during SARS-CoV-2 infection	[93]
7.	Gasdermin- D	Disulfiram	Inactivate gasdermin- D activity and thus prevent pro-inflammatory cytokine release from the inflammatory dead cells	[95]
8.	Glyceraldehyde 3-phosphate dehydrogenase	Dimethyl fumarate	Reprograms the metabolism in the pro-inflammatory macrophages and Tells so as to push them towards an anti-inflammatory state	[101]